
import type { Pipeline, TeamMember } from './types';

export const teamMembers: TeamMember[] = [
  { id: 'tm1', name: 'Dr. Evelyn Reed', avatarUrl: `https://i.pravatar.cc/40?u=tm1` },
  { id: 'tm2', name: 'Dr. Ben Carter', avatarUrl: `https://i.pravatar.cc/40?u=tm2` },
  { id: 'tm3', name: 'Dr. Alice Wong', avatarUrl: `https://i.pravatar.cc/40?u=tm3` },
  { id: 'tm4', name: 'Dr. Kenji Tanaka', avatarUrl: `https://i.pravatar.cc/40?u=tm4` },
];

export const pipelines: Pipeline[] = [
    {
        id: 'proj-001',
        name: 'Gliobax',
        status: 'Phase 2',
        progress: 60,
        lead: teamMembers[0],
        startDate: '2022-01-15T00:00:00.000Z',
        endDate: '2025-06-30T00:00:00.000Z',
        description: 'A novel compound for treating Glioblastoma Multiforme by targeting mutant IDH1.',
        dateCreated: '2022-01-10T00:00:00.000Z',
        phases: [
            { name: 'Preclinical', startDate: '2022-01-15', endDate: '2023-06-30', resources: [teamMembers[0], teamMembers[1]] },
            { name: 'Phase 1', startDate: '2023-07-01', endDate: '2024-06-30', resources: [teamMembers[0], teamMembers[2]] },
            { name: 'Phase 2', startDate: '2024-07-01', endDate: '2025-06-30', resources: [teamMembers[0], teamMembers[3]] }
        ],
        therapeuticArea: 'Oncology',
        indication: 'Glioblastoma Multiforme',
        mechanism: 'Targets mutant isocitrate dehydrogenase 1 (IDH1), leading to inhibition of tumor growth.',
        class: 'Small Molecule',
        target: 'IDH1 R132H',
        pharmacokinetics: 'Oral bioavailability of 45%; half-life of 12 hours.',
        company: 'OncoTherapeutics Inc.',
        companyLogoUrl: 'https://placehold.co/100x40.png',
        forecastSales: '$1.2B',
        patentExpiry: '2035-10-22',
        financials: {
          revenue: '$150M',
          operatingIncome: '$30M',
          netIncome: '$20M',
          totalAssets: '$500M',
          totalEquity: '$250M',
        },
    },
    {
        id: 'proj-002',
        name: 'CardiaHeal',
        status: 'Preclinical',
        progress: 35,
        lead: teamMembers[1],
        startDate: '2023-05-20T00:00:00.000Z',
        endDate: '2026-12-31T00:00:00.000Z',
        description: 'A gene therapy approach to regenerate cardiac tissue after myocardial infarction.',
        dateCreated: '2023-05-15T00:00:00.000Z',
        phases: [
            { name: 'Preclinical', startDate: '2023-05-20', endDate: '2026-12-31', resources: [teamMembers[1], teamMembers[3]] }
        ],
        therapeuticArea: 'Cardiology',
        indication: 'Heart Failure',
        mechanism: 'Delivers a payload of transcription factors via AAV vector to reprogram fibroblasts into cardiomyocytes.',
        class: 'Gene Therapy',
        target: 'Cardiac Fibroblasts',
        company: 'RegenMed Solutions',
        companyLogoUrl: 'https://placehold.co/100x40.png',
        forecastSales: '$2.5B',
    },
    {
        id: 'proj-003',
        name: 'NeuroCalm',
        status: 'Preclinical',
        progress: 15,
        lead: teamMembers[2],
        startDate: '2024-02-01T00:00:00.000Z',
        endDate: '2028-01-31T00:00:00.000Z',
        description: 'A selective GABA-A α5 subunit negative allosteric modulator for Alzheimers disease cognitive symptoms.',
        dateCreated: '2024-01-20T00:00:00.000Z',
        phases: [
             { name: 'Preclinical', startDate: '2024-02-01', endDate: '2028-01-31', resources: [teamMembers[2], teamMembers[0]] }
        ],
        therapeuticArea: 'Neurology',
        indication: 'Alzheimer\'s Disease',
        mechanism: 'Enhances cognitive function by modulating GABAergic inhibition in the hippocampus.',
        class: 'Nootropic',
        target: 'GABA-A Receptor α5',
        company: 'CogniGen Pharma',
        companyLogoUrl: 'https://placehold.co/100x40.png',
    },
    {
        id: 'proj-004',
        name: 'ArthriFlex',
        status: 'Phase 4',
        progress: 95,
        lead: teamMembers[3],
        startDate: '2021-08-10T00:00:00.000Z',
        endDate: '2025-09-15T00:00:00.000Z',
        description: 'An injectable monoclonal antibody targeting IL-17A for the treatment of rheumatoid arthritis.',
        dateCreated: '2021-08-01T00:00:00.000Z',
        phases: [
            { name: 'Preclinical', startDate: '2021-08-10', endDate: '2022-06-30', resources: [teamMembers[3]] },
            { name: 'Phase 1', startDate: '2022-07-01', endDate: '2023-03-31', resources: [teamMembers[3]] },
            { name: 'Phase 2', startDate: '2023-04-01', endDate: '2024-05-31', resources: [teamMembers[3]] },
            { name: 'Phase 3', startDate: '2024-06-01', endDate: '2024-12-31', resources: [teamMembers[3]] },
            { name: 'Phase 4', startDate: '2025-01-01', endDate: '2025-09-15', resources: [teamMembers[3]] }
        ],
        therapeuticArea: 'Immunology',
        indication: 'Rheumatoid Arthritis',
        mechanism: 'Neutralizes interleukin-17A, a key cytokine in the inflammatory cascade of RA.',
        class: 'Monoclonal Antibody',
        target: 'IL-17A',
        company: 'ImmunoCorp',
        companyLogoUrl: 'https://placehold.co/100x40.png',
        forecastSales: '$800M',
    },
    {
        id: 'proj-005',
        name: 'PulmoClear',
        status: 'Approved',
        progress: 100,
        lead: teamMembers[0],
        startDate: '2020-03-01T00:00:00.000Z',
        endDate: '2024-01-20T00:00:00.000Z',
        description: 'CFTR modulator for cystic fibrosis patients with the F508del mutation.',
        dateCreated: '2020-02-20T00:00:00.000Z',
         phases: [
            { name: 'Preclinical', startDate: '2020-03-01', endDate: '2021-02-28', resources: [teamMembers[0]] },
            { name: 'Phase 1', startDate: '2021-03-01', endDate: '2022-01-31', resources: [teamMembers[0]] },
            { name: 'Phase 2', startDate: '2022-02-01', endDate: '2023-05-30', resources: [teamMembers[0]] },
            { name: 'Phase 3', startDate: '2023-06-01', endDate: '2023-11-30', resources: [teamMembers[0]] },
            { name: 'Approved', startDate: '2024-01-20', endDate: '2024-01-20', resources: [teamMembers[0]] }
        ],
        therapeuticArea: 'Pulmonology',
        indication: 'Cystic Fibrosis',
        mechanism: 'Corrects the misfolded CFTR protein, allowing for proper chloride ion channel function.',
        class: 'CFTR Modulator',
        target: 'CFTR Protein',
        company: 'VitaBreathe Labs',
        companyLogoUrl: 'https://placehold.co/100x40.png',
        forecastSales: '$950M',
    },
     {
        id: 'proj-006',
        name: 'HepatoGuard',
        status: 'Phase 3',
        progress: 75,
        lead: teamMembers[2],
        startDate: '2021-11-01T00:00:00Z',
        endDate: '2025-12-31T00:00:00Z',
        description: 'An oral antiviral for the treatment of chronic Hepatitis B infection.',
        dateCreated: '2021-10-25T00:00:00Z',
        phases: [
            { name: 'Preclinical', startDate: '2021-11-01', endDate: '2022-10-31', resources: [teamMembers[2]] },
            { name: 'Phase 1', startDate: '2022-11-01', endDate: '2023-09-30', resources: [teamMembers[2], teamMembers[1]] },
            { name: 'Phase 2', startDate: '2023-10-01', endDate: '2024-12-31', resources: [teamMembers[2], teamMembers[1], teamMembers[3]] },
            { name: 'Phase 3', startDate: '2025-01-01', endDate: '2025-12-31', resources: [teamMembers[2], teamMembers[1], teamMembers[3]] }
        ],
        therapeuticArea: 'Infectious Disease',
        indication: 'Hepatitis B',
        mechanism: 'Inhibits HBV polymerase, halting viral replication.',
        class: 'Antiviral',
        target: 'HBV Polymerase',
        company: 'ViroLogics',
        companyLogoUrl: 'https://placehold.co/100x40.png',
        forecastSales: '$1.5B',
    },
];
